Callan Capital, LLC: IYW position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Callan Capital, LLC on IYW, newest first. How the timeline and the estimate are built.
Callan Capital, LLC held 1,713 IYW shares at 2025-03-31 per its 13F-HR filed 2025-04-29.
the latest 13F is the newest step
- period ended2025-03-3113F 1,713 sharesChange vs previous 13F -1 shares
0.02% of the 13F portfolio, value $240,574.
13F-HR 0001542166-25-000005 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 1,714 sharesChange vs previous 13F 0 shares
0.02% of the 13F portfolio, value $273,417.
13F-HR 0001542166-25-000003 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-09-3013F 1,714 sharesChange vs previous 13F 0 shares
0.02% of the 13F portfolio, value $259,877.
13F-HR 0001542166-24-000015 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-06-3013F/A 1,714 sharesChange vs previous 13F 0 shares
0.02% of the 13F portfolio, value $257,957.
13F-HR/A 0001542166-24-000013 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-03-3113F/A 1,714 sharesChange vs previous 13F 0 shares
0.02% of the 13F portfolio, value $231,493.
13F-HR/A 0001542166-24-000011 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2023-12-3113F 1,714 sharesChange vs previous 13F not available
0.02% of the 13F portfolio, value $210,394.
13F-HR 0001542166-24-000003 filed by Callan Capital, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).